Banner Health Foundation 5th Annual Alzheimer’s Disease, Lewy Body and Related Disorders Symposium 2026

1. Overview
The Banner Health Foundation 5th Annual Alzheimer’s Disease, Lewy Body and Related Disorders Symposium 2026 provides a comprehensive clinical update on the diagnosis, management, and emerging therapeutics for neurodegenerative diseases. The course explores advancements in biomarker utilization, monoclonal antibodies, neuropsychological evaluation, and specialized care strategies for complex dementia syndromes and movement disorders.
Course Date: 2026
2. Learning Objectives

Evaluate the role of neuropsychological testing and biomarkers in accurately diagnosing Alzheimer’s disease and distinguishing atypical presentations.

Analyze emerging therapeutics, including monoclonal antibodies, for the treatment of Alzheimer’s disease and their practical clinical implications.

Formulate comprehensive management plans for Lewy Body Dementia, Frontotemporal Dementia, and atypical parkinsonian syndromes like PSP and CBS.

Implement primary prevention strategies and address unique challenges in the cognitive evaluation of multilingual and diverse patient populations.

Assess the cognitive impact of deep brain stimulation (DBS) in Parkinson’s disease and develop intervention models to alleviate caregiver burden.

3. Target Audience

Best for neurologists, psychiatrists, and geriatricians who want updates on Alzheimer’s biomarkers, monoclonal antibodies, and related dementias.

4. Topics

01 Understanding the Role of Neuropsychologic Evaluation in Older Adults with Cognitive Concerns – Christine Belden, Ps…

02 Challenges in Cognitive Evaluation of Multilingual – Juan A. Serrano-Salcedo, PsyD

03 Primary Prevention and Risk Reduction in Dementia – Jeremy Pruzin, MD

04 Using Biomarkers to Diagnose Alzheimer’s Disease – Don’t Miss the Atypical Ones! – Po-Heng Tsai, MD

05 Q&A – Panel

06 The Future of Neurodegenerative Diseases – Alireza Atri, MD, PhD

07 Emerging Therapeutics in Alzheimer’s Disease- Monoclonal Antibodies to Amyloid and Beyond – Alireza Atri, MD, PhD…

08 Case Discussion – Nicholas Ashton, PhD

09 Diagnosis & Management of Lewy Body Dementia

10 Caregiver Burden Intervention Models – Lori Nisson, MSW, LCSW

11 Q&A – Panel

12 Case Discussion – Neuropsychiatric Symptoms in Alzheimer’s Disease and Related Disorders- Recognition and Treatme…

13 PSP and CBS. – Holly Laub-Brown, DO

14 E&M of Hyperkinetic and Drug-Induced Movement Disorders- State of the Art

15 Frontotemporal Dementia Syndromes – Andrew Ho, DO

16 Cognitive Impact of DBS in Parkinson’s Disease

17 Q&A – Panel

51th Annual Alzheimers Disease